Results 191 to 200 of about 11,256 (207)

Neue AGO-Leitlinie und Empfehlung zu PARPi

InFo Hämatologie + Onkologie, 2021
openaire   +1 more source

Real-world outcomes of poly(ADP)-ribose polymerase inhibitor (PARPi) monotherapy (PARPi mono) vs PARPi + bevacizumab (PARPi+bev ) first-line maintenance (1LM) therapy in patients (pts) with homologous recombination-deficient (HRd) advanced ovarian cancer (aOC)

Gynecologic Oncology
R. Wendel Naumann, Angeles Alvarez Secord, Nicole Niehoff, Rolee Das, Amanda Golembesky, Jonathan Lim, Matthias Hunger, Jaya Paranilam, Bhavana Pothuri   +8 more
openaire   +1 more source

PARPi-related myelodysplastic syndromes and AML

Reactions Weekly
openaire   +1 more source

Circulating Tumor DNA Monitoring in Ovarian Cancer Patients Receiving PARPi Maintenance Therapy: Can We Further Personalize Treatment?

Gynecologic Oncology
Kaitlyn Kincaid, Melissa Hardesty, Fibiana Oladipo   +2 more
exaly  

METHODS OF CANCER DETECTION USING PARPI-FL

2016
KOSSATZ SUSANNE, REINER THOMAS, WEBER WOLFGANG, PATEL SNEHAL G   +3 more
openaire   +3 more sources

Does PARP1 Up-Regulation Correlate With PSMA Expression in Patients With Metastatic Castration-Resistant Prostate Cancer Studied With [18F]PARPi and [68Ga]PSMA PET/CT?

European Journal of Nuclear Medicine and Molecular Imaging
Sazan Rasul, Ilva Kristiāna Langrate
exaly  

The nuclear shredder behind PARPi resistance

Nature Cell Biology
openaire   +1 more source

Arterial Hypertension Associated With PARPi: A Meta-Analysis of 41 Placebo Randomized Controlled Trials Combined With a World Health Organization's Pharmacovigilance Study

Fundamental and Clinical Pharmacology
Sophie Postel-Vinay, Jonaz Font, Angelique DA Silva   +2 more
exaly  

Quality of Life in Ovarian Cancer Patients Receiving Maintenance Therapy With Bevacizumab Versus PARPi: A Network Meta-Analysis

Expert Review of Anticancer Therapy
Ping Shi
exaly  

TE-PARPi as a precision weapon against hematologic cancers

Blood
openaire   +2 more sources